NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update Oncology

New WOSCAN protocols (May 2016)

The following West of Scotland Cancer Network (WOSCAN) protocols have been prepared in response to national guidance and are now available on the WOSCAN intranet site (NHS network access required):

Bevacizumab in combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Please note: the bevacizumab dose (7.5mg/kg) used in this regimen is outwith the licensed dose recommendation, however, clinical data and experience have demonstrated that efficacy and response to treatment is retained

  • For protocol click here
  • The GGC formulary entry has been updated. Click here
  • For relevant SMC advice click here

Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation

  • For protocol click here.  Please note that the WOSCAN protocol is for prednisolone instead of prednisone.
  • The GGC formulary has been updated. Click here
  • For relevant SMC advice click here

 

Idelalisib monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

  • For current protocol click herePlease note: in light of new findings from clinical trials, the MHRA has issued a drug safety update with information about the risk of serious and fatal infections with idelalisib and measures to minimise risk for all patients. The protocol is in the process of being updated and further advice will be issued when this new version is available on the intranet site
  • The GGC formulary has been updated. Click here
  • For relevant SMC advice click here

Ponatinib for the treatment of adult patients with:

  • Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
  • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) who are resistant to dasatinib; who are intolerant to dasatininb and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. 
    • For current protocol click here. Please note: the MHRA has issued a drug safety update about the risk of hepatitis B reactivation with BCR-ABL tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib and posatinib). Patients should be tested for hepatitis B virus before starting treatment with a BCR-ABL tyrosine kinase inhibitor. The protocol and CMG is in the process of being updated and further advice will be issued when the new versions are available on the intranet site
    • The GGC formulary has been updated. Click here
    • For relevant SMC advice click here